

REPOS THERAPEUTICS INC.
Form SC 13G
September 11, 2009

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G
Under the Securities Exchange Act of 1934
(Amendment No. __)*

Repos Therapeutics Inc.
(Name of Issuer)

Common Stock, \$0.001 par value per share
(Title of Class of Securities)

76028H100
(CUSIP Number)

September 8, 2009
(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

*The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be filed for the purpose of Section 18 of the Securities Exchange Act of 1934 (Act) or otherwise subject to the liabilities of that section of the Act but shall be subject to other provisions of the Act (however, see the Notes).

Edgar Filing: REPROS THERAPEUTICS INC. - Form SC 13G

(1)	Names of Reporting Persons.	ENABLE CAPITAL MANAGEMENT, LLC
		(a) £
(2)	Check the Appropriate Box if a Member of a Group (See Instructions)	(b) £
(3)	SEC Use Only	
(4)	Citizenship or Place of Organization	DELAWARE
	NUMBER OF	(5) Sole Voting Power
	SHARES	
	BENEFICIALLY	(6) Shared Voting Power
	OWNED BY EACH	1,500,000
	REPORTING	(7) Sole Dispositive Power
	PERSON WITH	
		(8) Shared Dispositive Power
		1,500,000
(9)	Aggregate Amount Beneficially Owned by Each Reporting Person	1,500,000
(10)	Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)	..
(11)	Percent of Class Represented by Amount in Row (9)	9.1%
(12)	Type of Reporting Person (See Instructions)	OO

Edgar Filing: REPROS THERAPEUTICS INC. - Form SC 13G

(1) Names of Reporting Persons.	ENABLE GROWTH PARTNERS, L.P.	
	(a) £	
(2) Check the Appropriate Box if a Member of a Group (See Instructions)	(b) £	
(3) SEC Use Only		
(4) Citizenship or Place of Organization	DELAWARE	
NUMBER OF	(5) Sole Voting Power	1,500,000
SHARES		
BENEFICIALLY	(6) Shared Voting Power	
OWNED BY EACH		
REPORTING	(7) Sole Dispositive Power	1,500,000
PERSON WITH		
	(8) Shared Dispositive Power	
(9) Aggregate Amount Beneficially Owned by Each Reporting Person		1,500,000
(10) Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)		..
(11) Percent of Class Represented by Amount in Row (9)		9.1 %
(12) Type of Reporting Person (See Instructions)		PN

Edgar Filing: REPROS THERAPEUTICS INC. - Form SC 13G

(1) Names of Reporting Persons.	MITCHELL S. LEVINE	
	(a) £	
(2) Check the Appropriate Box if a Member of a Group (See Instructions)	(b) £	
(3) SEC Use Only		
(4) Citizenship or Place of Organization	UNITED STATES	
NUMBER OF	(5) Sole Voting Power	
SHARES		
BENEFICIALLY	(6) Shared Voting Power	1,500,000
OWNED BY EACH		
REPORTING	(7) Sole Dispositive Power	
PERSON WITH		
	(8) Shared Dispositive Power	1,500,000
(9) Aggregate Amount Beneficially Owned by Each Reporting Person		1,500,000
(10) Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)		..
(11) Percent of Class Represented by Amount in Row (9)		9.1%
(12) Type of Reporting Person (See Instructions)		IN

Item 1(a). Name of Issuer:

Repros Therapeutics Inc.

Item 1(b). Address of Issuer's Principal Executive Offices:

2408 Timberloch Place, Suite B-7
The Woodlands, Texas 77380

Item 2(a). Names of Persons Filing:

Enable Capital Management, LLC (ECM)
Enable Growth Partners, L.P. (EGP)
Mitchell S. Levine

Item 2(b). Address of Principal Business Office or, if none, Residence:

The business address of the reporting persons is One Ferry Building, Suite 255, San Francisco, CA 94111.

Item 2(c). Citizenship:

Reference is made to Item 4 of pages 2, 3 and 4 of this Schedule 13G (this Schedule), which Items are incorporated by reference herein.

Item 2(d). Title of Class of Securities:

Common Stock, \$0.001 par value per share.

Item 2(e). CUSIP Number:

76028H100

Item 3. If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

- .. (a) Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o).
- .. (b) Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).
- .. (c) Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c).
- .. (d) Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).
- .. (e) An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);
- .. (f) An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);
- .. (g) A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
- .. (h) A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
- .. (i) A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
- .. (j) Group, in accordance with §240.13d-1(b)(1)(ii)(J).

Item 4. Ownership.

Reference is hereby made to Items 5-9 and 11 of pages 2, 3 and 4 of this Schedule, which Items are incorporated by reference herein.

The securities to which this Schedule relates (the Securities) are owned by EGP, an investment limited partnership for which ECM serves as general partner and investment manager. ECM, as EGP's general partner and investment manager, and Mitchell S. Levine, as managing member and majority owner of ECM, may therefore be deemed to beneficially own the Securities owned by EGP for the purposes of Rule 13d-3 of the Securities Exchange Act of 1934, as amended (the Act), insofar as they may be deemed to have the power to direct the voting or disposition of those Securities.

Neither the filing of this Schedule nor any of its contents shall be deemed to constitute an admission that ECM or Mr. Levine is, for any other purpose, the beneficial owner of any of the Securities, and each of ECM and Mr. Levine disclaims beneficial ownership as to the Securities, except to the extent of his or its pecuniary interests therein.

Under the definition of beneficial ownership in Rule 13d-3 under the Act, it is also possible that the individual general partners, executive officers, and members of the foregoing entities might be deemed the beneficial owners of some or all the Securities insofar as they may be deemed to share the power to direct the voting or disposition of the Securities. Neither the filing of this Schedule nor any of its contents shall be deemed to constitute an admission that any of such individuals is, for any purpose, the beneficial owner of any of the Securities, and such beneficial ownership is expressly disclaimed.

The calculation of percentage of beneficial ownership in Item 11 of pages 2, 3 and 4 was derived from the Issuer's Prospectus Supplement filed with the Securities and Exchange Commission on September 8, 2009, in which the Issuer stated that the number of shares of its Common Stock outstanding after the offering contemplated thereunder was 16,677,404 shares.

Item 5. Ownership of Five Percent or Less of a Class

Not applicable.

Item 6. Ownership of More than Five Percent on Behalf of Another Person.

Not applicable.

Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company

Not applicable.

Item 8. Identification and Classification of Members of the Group

Not applicable.

Item 9. Notice of Dissolution of Group

Not applicable.

